The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world recurrence and survival in locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) treated with surgery and adjuvant radiotherapy with or without systemic therapy: A SEER-Medicare analysis.
 
Dandan Zheng
Employment - Abbvie (I); Merck
Stock and Other Ownership Interests - Merck
 
Su Zhang
Consulting or Advisory Role - Merck (Inst)
 
Behzad Bidadi
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
Travel, Accommodations, Expenses - Merck
 
Nati Lerman
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yuexin Tang
Employment - Merck; Moderna Therapeutics (I)
Stock and Other Ownership Interests - Merck; Moderna Therapeutics (I)
 
Yan Song
Consulting or Advisory Role - Merck (Inst)
 
Rui Song
Consulting or Advisory Role - Merck (Inst)
 
Jiayang Li
Consulting or Advisory Role - Merck (Inst)
 
Anyu Zhu
Consulting or Advisory Role - Merck (Inst)
 
Sanjay Merchant
Employment - Merck
Stock and Other Ownership Interests - Merck
 
James Signorovitch
Consulting or Advisory Role - Merck (Inst)
 
Glenn Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Massachusetts Medical Society
Consulting or Advisory Role - Adela; Astellas Pharma; AstraZeneca; Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Coherus Biosciences; Coherus Biosciences; CorriXr; Curie.Bio; Elevar Therapeutics; Grey Wolf Therapeutics; Guardian Bio; InhibRx; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Nextech Invest; OncoSwitch; Ottimo; Outrun; PDS Biotechnology; Pyxis; Regeneron; Remix Therapeutics; Replimune; Rgenta; Surface Oncology; TD Cowan; Tubulis GmbH
Research Funding - Actuate Therapeutics (Inst); Adenoid Cystic Carcinoma Research Foundation (Inst); ASCO (Inst); Astellas Pharma (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Cellestia Biotech (Inst); Coherus Biosciences (Inst); Exelixis (Inst); Gateway for Cancer Research; Genentech (Inst); ImmunityBio (Inst); KSQ Therapeutics (Inst); Kura Oncology (Inst); PHASE ONE Foundation (Inst); Regeneron (Inst); Remix Therapeutics (Inst); Rgenta (Inst); Secura Bio (Inst); Secura Bio (Inst)
Other Relationship - Tubulis GmbH